Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,277 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Completed Phase 1 Interventional Results available

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

NCT02565628
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
PF-06669571, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
New Haven, Connecticut • Hallandale, Florida • Hollywood, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

NCT00234819
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • Fort Myers, Florida • North Port Richey, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

NCT01337765
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
Interventions
BEZ235 + MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 4 Interventional

Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).

NCT00140036
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Blood draw
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
29
States / cities
Mobile, Alabama • Tucson, Arizona • Fresno, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

NCT00880581
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell, Lymphomas: Non-Hodgkin
Interventions
PF-3512676, Local radiotherapy
Drug · Radiation
Lead sponsor
Ronald Levy
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

NCT00265330
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
41
States / cities
Scottsdale, Arizona • San Diego, California • Aurora, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

NCT05677867
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

NCT01302119
View directory record Official record
Conditions
Onychomycosis of Toenails
Interventions
AN2690 Topical Solution, 5%, Solution Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Novato, California • Oceanside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 29, 2026, 4:46 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Irvine, California • Santa Ana, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 29, 2026, 4:46 AM EDT
Active, not recruiting No phase listed Observational

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

NCT05160636
View directory record Official record
Conditions
COVID-19, Coronavirus Disease 2019, Influenza
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

Rimegepant in Moderate Plaque-type Psoriasis

NCT04629950
View directory record Official record
Conditions
Psoriasis
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 3 Interventional

A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients

NCT00002140
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Berkeley, California • Mill Valley, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 4:46 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

NCT04281485
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
PF-06939926, Placebo
Genetic · Other
Lead sponsor
Pfizer
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2039
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 29, 2026, 4:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

NCT01677065
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone controlled-release test formulation, Immediate-release reference drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 29, 2026, 4:46 AM EDT
Terminated Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

NCT00267267
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia
Interventions
torcetrapib/atorvastatin, ezetimibe/simvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
123
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 29, 2026, 4:46 AM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

NCT02342548
View directory record Official record
Conditions
Huntington's Disease
Interventions
20 mg BID of PF-02545920
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 66 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Results available

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

NCT03538743
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, PF-06882961
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Anaheim, California • South Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 29, 2026, 4:46 AM EDT
Active, not recruiting Phase 1 Interventional

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT03498378
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Avelumab, Palbociclib, Cetuximab
Drug
Lead sponsor
Kathryn Gold
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 29, 2026, 4:46 AM EDT
Completed No phase listed Observational

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

NCT00161668
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Mylotarg
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
59
States / cities
Tucson, Arizona • Berkely, California • Burbank, California + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2007 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

NCT01356628
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, HCC, Liver Cancer
Interventions
PD-0332991
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 29, 2026, 4:46 AM EDT
Recruiting No phase listed Observational

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

NCT04398628
View directory record Official record
Conditions
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
76
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo comparator
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.

NCT00661765
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline tartrate, varenicline free base
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2009 · Synced Oct 29, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

NCT00678392
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
Axitinib (AG-013736), Sorafenib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
161
States / cities
Burbank, California • Downey, California • Glendale, California + 103 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 29, 2026, 4:46 AM EDT